Steen Husted

Summary

Publications

  1. doi request reprint Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with atherothrombosis?
    Steen Husted
    Medical Cardiological Department A, Aarhus University Hospital, Aarhus C, Denmark
    Int J Cardiol 134:150-9. 2009
  2. ncbi request reprint The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
    Steen Husted
    Medical Department, Hospital Unit West, GI, Landevej 61, Herning 7400, Denmark
    Eur Heart J 35:1541-50. 2014
  3. ncbi request reprint Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial
    Steen Husted
    Department of Cardiology, Arhus University Hospital, Arhus, Denmark
    Circ Cardiovasc Qual Outcomes 5:680-8. 2012
  4. doi request reprint Antiplatelet therapy in acute coronary syndromes: ticagrelor
    Steen Husted
    Medical Department, Hospital Unit West, Herning, Denmark
    Adv Cardiol 47:64-77. 2012
  5. doi request reprint Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies
    Steen E Husted
    Department of Cardiology, Arhus University Hospital, Arhus C, Denmark
    Clin Pharmacokinet 51:397-409. 2012
  6. doi request reprint Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes
    Steen Husted
    Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
    Postgrad Med 123:79-90. 2011
  7. ncbi request reprint [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]
    Steen Elkjaer Husted
    Medicinsk kardiologisk afdeling, Arhus Sygehus, Arhus Universitetshospital, 8000 Arhus C, Denmark
    Ugeskr Laeger 172:2888-91. 2010
  8. ncbi request reprint [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]
    Steen Elkjaer Husted
    Medicinsk kardiologisk afdeling, Arhus Sygehus, Arhus Universitets horpital, 8000 Arhus C, Denmark
    Ugeskr Laeger 172:2522-6. 2010
  9. doi request reprint Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel
    Steen Husted
    Arhus University Hospital, Arhus, Denmark
    Clin Cardiol 33:206-12. 2010
  10. pmc Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
    Steen Husted
    Department of Medicine and Cardiology, Aarhus University Hospital, DK 8000 Aarhus, Denmark
    Cardiovasc Ther 27:259-74. 2009

Detail Information

Publications17

  1. doi request reprint Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with atherothrombosis?
    Steen Husted
    Medical Cardiological Department A, Aarhus University Hospital, Aarhus C, Denmark
    Int J Cardiol 134:150-9. 2009
    ..It then goes on to examine the consequences of non-adherence and explores ways in which adherence may be improved from the perspective of both the physician and the patient...
  2. ncbi request reprint The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
    Steen Husted
    Medical Department, Hospital Unit West, GI, Landevej 61, Herning 7400, Denmark
    Eur Heart J 35:1541-50. 2014
    ....
  3. ncbi request reprint Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial
    Steen Husted
    Department of Cardiology, Arhus University Hospital, Arhus, Denmark
    Circ Cardiovasc Qual Outcomes 5:680-8. 2012
    ..This prespecified analysis investigates the effect and treatment-related complications of ticagrelor versus clopidogrel in elderly patients (≥75 years of age) with acute coronary syndrome compared with those <75 years of age...
  4. doi request reprint Antiplatelet therapy in acute coronary syndromes: ticagrelor
    Steen Husted
    Medical Department, Hospital Unit West, Herning, Denmark
    Adv Cardiol 47:64-77. 2012
    ..Hence, the PLATO population reflected specifically those patients who would ordinarily receive thienopyridine-based antiplatelet therapy in a clinical setting...
  5. doi request reprint Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies
    Steen E Husted
    Department of Cardiology, Arhus University Hospital, Arhus C, Denmark
    Clin Pharmacokinet 51:397-409. 2012
    ..We now report the pharmacokinetic analyses of ticagrelor, and the exposure-inhibition of platelet aggregation (IPA) relationships from these studies...
  6. doi request reprint Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes
    Steen Husted
    Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
    Postgrad Med 123:79-90. 2011
    ..This review places the PLATO data in context, and assesses the role that ticagrelor may play in treating patients with ACS...
  7. ncbi request reprint [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]
    Steen Elkjaer Husted
    Medicinsk kardiologisk afdeling, Arhus Sygehus, Arhus Universitetshospital, 8000 Arhus C, Denmark
    Ugeskr Laeger 172:2888-91. 2010
    ..No net clinical benefit of LMWH was found compared to UHF, but LMWH has pharmacokinetic advantages. The optimal duration of heparin treatment remains controversial...
  8. ncbi request reprint [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]
    Steen Elkjaer Husted
    Medicinsk kardiologisk afdeling, Arhus Sygehus, Arhus Universitets horpital, 8000 Arhus C, Denmark
    Ugeskr Laeger 172:2522-6. 2010
    ..No net clinical benefit of LMWH was found compared to UHF, but LMWH has pharmacokinetic advantages. The optimal duration of heparin treatment remains controversial...
  9. doi request reprint Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel
    Steen Husted
    Arhus University Hospital, Arhus, Denmark
    Clin Cardiol 33:206-12. 2010
    ....
  10. pmc Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
    Steen Husted
    Department of Medicine and Cardiology, Aarhus University Hospital, DK 8000 Aarhus, Denmark
    Cardiovasc Ther 27:259-74. 2009
    ..The efficacy and safety of ticagrelor are being further evaluated in the phase III PLATO trial, involving approximately 18,000 patients with ACS, including both ST-elevation and non-ST-elevation ACS...
  11. doi request reprint Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial
    S Husted
    Arhus University Hospital, Arhus, Denmark
    Int J Clin Pract 63:667-70. 2009
    ..Further prospective studies are planned to assess the relationship between this potential clinical benefit of AZD6140 and the reversibility of its antiplatelet effects...
  12. ncbi request reprint Trend in mortality after stroke with atrial fibrillation
    Lars Frost
    Department of Cardiology A, Aarhus University Hospital, Aarhus, Denmark
    Am J Med 120:47-53. 2007
    ..We estimated trends separately for each sex in unadjusted analyses. We also adjusted for age, comorbid conditions, and general trend in mortality in the background population...
  13. doi request reprint Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey
    Axel Brandes
    Department of Cardiology, Odense University Hospital, Odense, Denmark
    Clin Cardiol 36:427-32. 2013
    ..The aim of this prospective survey was to describe the demographics, stroke risk profile, and the guideline adherence of antithrombotic treatment in a Danish primary care population of patients with nonvalvular atrial fibrillation (AF)...
  14. ncbi request reprint Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
    Steen Husted
    Department of Medicine and Cardiology, Arhus University Hospital, Denmark
    Eur Heart J 27:1038-47. 2006
    ..This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of AZD6140, the first oral, reversible adenosine diphosphate (ADP) receptor antagonist...
  15. ncbi request reprint Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents
    Steen Husted
    Department of Medicine and Cardiology, Arhus University Hospital, DK 8000 Arhus C, Arhus, Denmark
    Fundam Clin Pharmacol 23:1-9. 2009
    ..AZD6140 is being compared with clopidogrel in PLATO, a phase III trial in approximately 18000 ACS patients...
  16. doi request reprint Venous thromboembolism in patients having knee replacement and receiving thromboprophylaxis: a Danish population-based follow-up study
    Alma B Pedersen
    Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43 45, 8200 Aarhus N, Denmark
    J Bone Joint Surg Am 93:1281-7. 2011
    ..We examined the rate of venous thromboembolism, as well as changes over time, in a population-based cohort of patients who underwent knee arthroplasty...
  17. ncbi request reprint Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002
    Lars Frost
    Department of Cardiology A, Aarhus University Hospital, Denmark
    Neuroepidemiology 26:212-9. 2006
    ....